MedTrace Logo

Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers

NCT00097747 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2012-12-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and minimum pharmacologically active dose of peginesatide in Healthy Volunteers.

Conditions

Interventions

DRUG

Placebo

DRUG

peginesatide

Sponsors & Collaborators

  • Affymax

    lead INDUSTRY

Principal Investigators

  • Affymax · Affymax, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2005-01-31
Completion
2005-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00097747 on ClinicalTrials.gov